Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

EZH2 protein may aid prognostication in resected NSCLC

A protein called “enhancer of zeste homolog-2” is frequently expressed in non-small-cell lung cancer and may have prognostic value following surgical resection, US researchers believe.

30 Oct 2013

Complement protein holds diagnostic, prognostic promise in lung cancer

A complement activation product known as “C4d” may have value as a diagnostic and prognostic biomarker for lung cancer, research suggests.

28 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.

23 Oct 2013

REGARD VEGF receptor-2 as gastric cancer target

Targeting vascular endothelial growth factor receptor-2 mediated signaling is an effective strategy against advanced gastric cancer, results from the REGARD trial demonstrate.

22 Oct 2013

Study: Elevated BMI may affect survival in pancreatic cancer patients

New results from a prospective study published in the Journal of Clinical Oncology show that patients with a body mass index (BMI) in the obese range live on average two to three months less after a pancreatic cancer diagnosis, compared with healthy weight patients, even after adjusting for factors that are known to predict survival for patients with this disease, such as age and disease stage.

22 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

NEJM publishes Celgene’s Abraxane phase III study results

Published today in the New England Journal of Medicine, a phase III clinical trial of Abraxane (paclitaxel formulated as albumin-bound nanoparticles) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].

17 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Mayo Clinic: Physical activity is associated with reduced risk of esophageal cancer

Physical activity is associated with a reduced risk of esophageal cancer, according to a new study presented by Mayo Clinic researchers at the American College of Gastroenterology's Annual Scientific Meeting, Oct. 11-16, in San Diego.

15 Oct 2013

Researchers identify genetic variants associated with Barrett's and esophageal cancer

An international consortium co-led by researchers at Fred Hutchinson Cancer Research Center and the QIMR Berghofer Medical Research Institute in Australia has identified four genetic variants associated with an increased risk of esophageal cancer and its precursor, a condition called Barrett's esophagus.

14 Oct 2013

UCSD surgeons perform first robotic gastrectomy for gastric cancer treatment

Surgeons at UC San Diego Health System have performed the region's first robotic gastrectomy, a potentially lifesaving procedure to remove a section of the stomach after a diagnosis of gastric cancer. Aided by a da Vinci robot, surgeons remove the diseased tissue, perform a delicate reconstruction and remove local lymph nodes for further testing.

3 Oct 2013

Study shows direct causative link between obesity and risk of pancreatic cancer in mice

Researchers at UCLA's Jonsson Comprehensive Cancer Center (JCCC) have found that mice made obese by being given high-calorie, high-fat diets (HFCD) developed abnormally high numbers of lesions known as pancreatic intraepithelial neoplasias (PanINs), which are known to be precursors to pancreas cancer.

1 Oct 2013

Time to first cigarette independently predicts lung cancer

The time to first cigarette after waking is an independent risk factor for lung cancer, a Japanese case-control study has found.

27 Sep 2013

New class of antidepressants appears potentially effective in combating deadly form of lung cancer

A little-used class of antidepressants appears potentially effective in combating a particularly deadly form of lung cancer, according to a new study from researchers at the Stanford University School of Medicine.

27 Sep 2013

miR-31 in primary tumor cells predicts lymph node metastasis in NSCLC patients

Determining whether a patient's lung cancer has spread to nearby lymph nodes is critical for identifying the most effective therapy, but it usually requires surgery. A new study suggests, however, that measuring levels of a particular molecule in a sample of tumor tissue might accurately answer the question.

25 Sep 2013

Protein pair may be prognostic biomarker for identifying smoking-related lung cancers

Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene.

20 Sep 2013

Study reports identification of IDH1 protein as novel biomarker for diagnosis of NSCLC

A protein called isocitrate dehydrogenase is present at high levels in lung cancers and can be detected in the blood, making it a noninvasive diagnostic marker for lung cancers, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

17 Sep 2013

GGO-dominant lung tumors have excellent prognosis

Ground glass opacity-dominant clinical stage IA lung adenocarcinoma is a low-grade malignancy with an “excellent” prognosis, Japanese researchers believe.

10 Sep 2013

Adenocarcinoma News and Research

Further Reading

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

EZH2 protein may aid prognostication in resected NSCLC

Complement protein holds diagnostic, prognostic promise in lung cancer

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

REGARD VEGF receptor-2 as gastric cancer target

Study: Elevated BMI may affect survival in pancreatic cancer patients

New investigational drug offers potential treatment option for lung cancer

NEJM publishes Celgene’s Abraxane phase III study results

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Mayo Clinic: Physical activity is associated with reduced risk of esophageal cancer

Researchers identify genetic variants associated with Barrett's and esophageal cancer

UCSD surgeons perform first robotic gastrectomy for gastric cancer treatment

Study shows direct causative link between obesity and risk of pancreatic cancer in mice

Time to first cigarette independently predicts lung cancer

New class of antidepressants appears potentially effective in combating deadly form of lung cancer

miR-31 in primary tumor cells predicts lymph node metastasis in NSCLC patients

Protein pair may be prognostic biomarker for identifying smoking-related lung cancers

Study reports identification of IDH1 protein as novel biomarker for diagnosis of NSCLC

GGO-dominant lung tumors have excellent prognosis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News